Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldoxorubicin in Advanced Pancreatic Ductal Carcinoma
NCT01580397Phase 2Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- May 2012
- Primary completion
- May 2013
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aldoxorubicin in pancreatic ductal adenocarcinoma (PDAC), sponsored by ImmunityBio, Inc.. Started May 2012; status: completed.
02
Drugs
aldoxorubicin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01580397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01580397.